Thymosin Beta-4 (TB-500) is a synthetic peptide research material supplied for controlled laboratory analysis and in vitro experimentation. It is commonly examined in studies involving actin binding, cytoskeletal organization, cell-migration-associated markers, and related molecular signaling systems.
Laboratory studies may use TB-500 to characterize peptide identity, interactions with monomeric G-actin, concentration-dependent molecular responses, and other predefined analytical endpoints. References to actin dynamics, cell migration, endothelial-derived cells, or extracellular matrix-associated markers describe laboratory research categories only.
These experimental contexts do not indicate that TB-500 heals, repairs, regenerates, protects, or changes human or animal tissue. Lot-specific analytical documentation is available through the Nordsci Certificate of Analysis Library.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Thymosin Beta-4 (TB-500) is a synthetic peptide research material supplied as a lyophilized powder for controlled laboratory analysis and in vitro experimentation. The material is commonly evaluated in studies involving actin binding, cytoskeletal organization, cell-migration-associated markers, and related molecular signaling systems.
Thymosin Beta-4 is a 43-amino-acid peptide associated with the beta-thymosin family. Its interaction with monomeric G-actin provides laboratories with a defined molecular system for receptor-independent binding assays, cytoskeletal studies, and comparative peptide analysis.
References to cellular migration, cytoskeletal activity, endothelial-derived cells, dermal-derived cells, cardiac-derived cells, or neural-derived cells identify laboratory models and analytical endpoints only. They do not indicate that TB-500 repairs, regenerates, heals, protects, or changes tissue in humans or animals.
Thymosin Beta-4 Research Peptide Specifications:
| Compound | Thymosin Beta-4 (TB-500) |
| Unit Size | 5mg or 10mg per vial |
| Unit Quantity | 1 vial |
| Sequence | Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH |
| Molecular Formula | C212H350N56O78S |
| Molecular Weight | Approximately 4963.5 g/mol |
| CAS Number | 77591-33-4 |
| Compound Type | Synthetic peptide research material |
| Form | Lyophilized powder |
| Source | Chemical synthesis |
| Purity / Identity | Refer to the lot-specific Certificate of Analysis |
| Analytical Documentation | Lot-specific documentation may report HPLC, mass spectrometry, or other applicable analytical results |
| Storage Conditions | Store sealed at −20°C or below and protect from light, heat, and moisture unless otherwise stated in the applicable documentation |
| Research Classification | Laboratory research and analytical use only |
| Restrictions | Not for human or animal consumption or in vivo, diagnostic, therapeutic, food, drug, cosmetic, or dietary-supplement use |
Thymosin Beta-4 is a naturally occurring member of the beta-thymosin peptide family. Synthetic Thymosin Beta-4 research material allows laboratories to examine its molecular characteristics and actin-associated interactions under controlled experimental conditions.
A principal area of laboratory investigation involves the interaction between Thymosin Beta-4 and monomeric G-actin. Actin is a structural protein involved in cytoskeletal organization, and its molecular state can be studied through binding assays, polymerization measurements, imaging systems, and other validated analytical methods.
Researchers may also examine TB-500-associated observations in different cell-derived models. Applicable endpoints can include actin-binding activity, cytoskeletal distribution, cell-migration-associated measurements, protein-expression markers, or other assay-specific molecular responses.
Results from these experiments remain specific to the selected model, controls, concentration range, exposure period, and analytical method. In vitro findings do not establish wound-related, regenerative, cardiovascular, neurological, anti-inflammatory, or therapeutic effects.
Important Research Notice: Nordsci research materials are supplied with access to lot-specific analytical documentation. Researchers should consult the applicable Certificate of Analysis for reported identity and purity information.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR IN VIVO, DIAGNOSTIC, THERAPEUTIC, FOOD, DRUG, COSMETIC, OR DIETARY-SUPPLEMENT USE.
TB-500 may be evaluated in controlled biochemical assays designed to characterize its interaction with monomeric G-actin. Applicable endpoints can include binding affinity, complex formation, actin availability, or other validated molecular measurements.
Observed activity remains specific to the assay conditions and should not be interpreted as evidence of an effect on human or animal tissue.
Laboratories may use TB-500 in cell-based models designed to measure cytoskeletal distribution or actin-associated molecular markers. Experimental plans should define the cell type, concentration range, exposure period, imaging method, and acceptance criteria before testing.
Cytoskeletal observations do not establish healing, repair, regeneration, physical recovery, or structural outcomes.
Controlled in vitro studies may examine migration-associated endpoints in selected cell-derived systems. These endpoints can include movement across a defined surface, assay closure measurements, cytoskeletal localization, or other standardized observations.
The phrase “cell migration” describes an in vitro measurement. It does not indicate wound closure, tissue repair, angiogenesis, or a physiological effect in humans or animals.
Researchers may compare TB-500 with untreated controls, vehicle controls, or other peptide research materials such as BPC-157, GHK-Cu, or KPV.
Comparative study designs can help distinguish compound-associated observations from background activity. Differences between experimental groups should be interpreted only within the limitations of the selected model, controls, methods, and analytical endpoints.
TB-500 should be handled only by qualified laboratory personnel using established procedures for synthetic peptide research materials. Laboratories should document product receipt, lot identification, storage conditions, sample allocation, testing methods, and disposal.
No reconstitution volume, diluent selection, concentration, dosing, injection, administration, topical application, or in vivo use guidance is provided.
Protocol Design Considerations:
Note: This information is provided exclusively as a laboratory research reference. All work should be conducted by qualified personnel in appropriately equipped facilities and in accordance with applicable institutional requirements.
Lot-specific Certificates of Analysis provide analytical information associated with the applicable TB-500 product lot. Documentation may include identity, purity, testing methodology, and other reported analytical results.
Researchers should confirm that the lot number on the vial corresponds with the lot number shown on the applicable COA. Analytical findings apply only to the tested lot and should not be interpreted as evidence of clinical safety, effectiveness, or approval for human or veterinary use.
Nordsci Peptides supplies TB-500 in 5mg and 10mg vial sizes as a laboratory research material with access to lot-specific analytical documentation. Laboratories should evaluate compound identity, reported analytical results, storage requirements, batch traceability, and institutional procurement standards before use.
Procurement Guidelines for Research Institutions
IMPORTANT: TB-500 is sold exclusively for laboratory research and analytical use. It is not a drug, food, dietary supplement, cosmetic, or therapeutic product. It is not approved for human or veterinary use and must not be used for consumption, diagnosis, treatment, prevention, compounding, topical application, or any in vivo procedure.
